

From: dph.immunizations@ct.gov <noreply@everbridge.net>
Sent: Monday, July 31, 2023 11:08 AM
Subject: New Menveo Formulation



DEPARTMENT OF PUBLIC HEALTH

Please see the attached memo.

Mick Bolduc
Epidemiologist/Vaccine Coordinator
Connecticut Immunization Program
410 Capitol Avenue, MS # 11MUN
Hartford, CT 06134-0308
Phone: (860) 509-7929
Fax: (860) 706-5429

If you would like to subscribe to receive these communications, please complete [this form](#). If you would like to unsubscribe from receiving these communications, please complete [this form](#).

STATE OF CONNECTICUT


DEPARTMENT OF PUBLIC HEALTH

Manisha Juthani, MD
Commissioner



Ned Lamont
Governor
Susan Bysiewicz
Lt. Governor

Immunization Program

TO: All CVP Providers
FROM: Mick Bolduc 
Vaccine Coordinator, Connecticut Immunization Program
DATE: July 31, 2023
SUBJECT: New Menveo Formulation

The purpose of this communication is to notify you of a new liquid formulation for Glaxo SmithKline's (GSK) [Menveo](#) vaccine as well as a change in the age indication with the new formulation.

Menveo

On September 1, 2023 the CVP will make available GSK's Menveo single dose vial presentation (NDC # 58160-0827-30, 10-pack) which does not require reconstitution. Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135.

The single dose vial presentation is approved for use in individuals 10 through 55 years of age. These age indications are slightly different than the 2-vial presentation that has been available (NDC 58160-0955-09, 5-pack) which is approved for use in persons aged 2 months through 55 years.

GSK will continue to make both products available to support vaccination for children as young as 2 months of age. However, the Menveo 2-vial presentation (NDC 58160-0955-09) will be available in limited amounts, therefore it will be important to target this product for use in children aged 2 months through 2 years of age, since it is the only meningococcal conjugate approved for use in this age group.

To ensure the equitable availability of the Menveo 2-vial (NDC 58160-0955-09), CDC will place this vaccine on allocation once Menveo single dose vial (NDC 58160-0827-30) becomes available. Starting September 1, 2023 providers who have existing stock of NDC 58160-0955-09 should use this vaccine for their patients aged 2 months through 2 years of age only.

As always if you have any questions, please feel free to contact me at (860) 509-7929.



Phone: (860) 509-7929 • Fax: (860) 706-5429
Telecommunications Relay Service 7-1-1
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
<https://portal.ct.gov/dph>

Affirmative Action/Equal Opportunity Employer

